Translate Bio, Inc. TBIO
We take great care to ensure that the data presented and summarized in this overview for Translate Bio, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in TBIO
Top Purchases
Top Sells
About TBIO
Insider Transactions at TBIO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 14
2021
|
Jean Francois Formela Director |
SELL
Open market or private sale
|
Indirect |
2,055,063
-100.0%
|
$78,092,394
$38.0 P/Share
|
|
Sep 14
2021
|
Owen Hughes Director |
SELL
Open market or private sale
|
Direct |
29,860
-100.0%
|
$1,134,680
$38.0 P/Share
|
|
Sep 14
2021
|
Paul D. Burgess Chief Operating Officer, CLO |
SELL
Open market or private sale
|
Direct |
71,833
-100.0%
|
$2,729,654
$38.0 P/Share
|
|
Sep 14
2021
|
Ronald C Renaud Jr Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
450,822
-100.0%
|
$17,131,236
$38.0 P/Share
|
|
Sep 14
2021
|
Ronald C Renaud Jr Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
503,231
-100.0%
|
$19,122,778
$38.0 P/Share
|
|
Sep 14
2021
|
Sanofi > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
71,983,597
+34.8%
|
$2,735,376,686
$38.0 P/Share
|
|
Apr 07
2021
|
Ronald C Renaud Jr Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,026
+1.76%
|
$63,182
$7.39 P/Share
|
|
Jan 14
2021
|
Ronald C Renaud Jr Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,639
+0.56%
|
$39,473
$7.87 P/Share
|
|
Dec 22
2020
|
Jean Francois Formela Director |
SELL
Open market or private sale
|
Indirect |
82,565
-34.46%
|
$2,064,125
$25.46 P/Share
|
|
Dec 21
2020
|
Jean Francois Formela Director |
SELL
Open market or private sale
|
Indirect |
56,536
-30.89%
|
$1,413,400
$25.5 P/Share
|
|
Nov 16
2020
|
Ronald C Renaud Jr Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
53,007
+4.89%
|
$371,049
$7.87 P/Share
|
|
Jun 26
2020
|
Baupost Group LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
500,000
+2.7%
|
$11,000,000
$22.0 P/Share
|
|
Jul 02
2018
|
Glaxosmithkline PLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
269,230
+6.79%
|
$3,499,990
$13.0 P/Share
|
|
Jul 02
2018
|
Glaxosmithkline PLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,428,682
+30.71%
|
-
|
Last 12 Months Summary
Buy / Acquisition
0
Shares
From
0
Insiders
Sell / Disposition
0
Shares
From
0
Insiders